Prospects for the development of adjuvant therapy for non-small cell lung cancer

The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total lung resection is adjuvant chemotherapy, nowadays. The 5-year survival benefit for this approach is about 5%, and the risk of relapse reduces from 11 to 15%, depend...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: K. K. Laktionov, A. M. Kazakov, E. V. Reutova, M. S. Ardzinba, A. L. Arzumanian
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2020
Materias:
Acceso en línea:https://doaj.org/article/0ce8e5769b2f4663b26654a8a7d6d7e7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!